2-Methylpyridine-3-boronic acid
Product Information
Molecular Formula
C6H8BNO2
Molecular Weight
136.94
Description
2-Methylpyridine-3-boronic acid is a paramount compound within the biomedical industry and demonstrates its significance in pharmaceutical synthesis. Posing as a crucial pharmaceutical intermediate, it effectively enables the creation of anti-cancer medications like proteasome inhibitors. By obstructing designated cellular processes, this product plays an indispensable role in the amelioration of diverse diseases, notably certain cancer typologies.
Synonyms
(2-methylpyridin-3-yl)boronic acid; 2-METHYLPYRIDINE-3-BORONIC ACID; 2-Methylpyridin-3-ylboronic acid; 2-Methyl-3-pyridinylboronic acid; 3-Borono-2-methylpyridine; 2-Picoline-3-boronic acid; 2-methylpyridin-3-ylboronicacid; 2-methyl-3-pyridineboronic acid; (2-methyl-3-pyridinyl)boronic acid; 2-METHYLPYRIDINE-3-BORONICACID; Boronic acid, (2-methyl-3-pyridinyl)-; 2-Methyl-pyridine 3-boronic acid; (2-methylpyridin-3-yl)boronicacid
IUPAC Name
(2-methylpyridin-3-yl)boronic acid
SMILES
B(C1=C(N=CC=C1)C)(O)O
InChI
InChI=1S/C6H8BNO2/c1-5-6(7(9)10)3-2-4-8-5/h2-4,9-10H,1H3
InChI Key
TWKMYNQPIICYNV-UHFFFAOYSA-N
Flash Point
Not applicable
Safety Information
Hazards
H315 - H318 - H335
Precautionary Statement
P280 - P302 + P352 - P305 + P351 + P338 + P310
Computed Properties
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
1
Exact Mass
137.0648087 g/mol
Monoisotopic Mass
137.0648087 g/mol
Topological Polar Surface Area
53.4Ų
Heavy Atom Count
10
Formal Charge
0
Complexity
110
Isotope Atom Count
0
Defined Atom Stereocenter Count
0
Undefined Atom Stereocenter Count
0
Defined Bond Stereocenter Count
0
Undefined Bond Stereocenter Count
0
Covalently-Bonded Unit Count
1
Compound Is Canonicalized
Yes
Patents
| Publication Number | Title | Priority Date |
|---|---|---|
| CN-113860980-A | Method for preparing arylamine compound by photoinduced reduction C-N coupling reaction | 2021-10-11 |
| WO-2021252555-A1 | Collagen 1 translation inhibitors and methods of use thereof | 2020-06-09 |
| WO-2021194326-A1 | Aminopyrimidine derivatives and their use as aryl hydrocarbon receptor modulators | 2020-03-27 |
| US-2021269434-A1 | Tricyclic compounds as inhibitors of kras | 2020-01-10 |
| WO-2021142252-A1 | Tricyclic compounds as inhibitors of kras | 2020-01-10 |
| WO-2021076945-A1 | Tropolone derivatives and tautomers thereof for iron regulation in animals | 2019-10-16 |
| WO-2021000935-A1 | Hpk1 inhibitors and uses thereof | 2019-07-04 |
| TW-202116751-A | Hpk1 inhibitors and uses thereof | 2019-07-04 |
| WO-2020247679-A1 | Wdr5 inhibitors and modulators | 2019-06-04 |
| WO-2020191261-A1 | Indazoles as lrrk2 inhibitors | 2019-03-21 |
